Key result
Conservative treatment of elderly NSTEMI is linked to ~212% higher major cardiovascular events risk versus invasive care.
Why the study?
Optimal treatment for elderly patients with NSTEMI is debated, and whether a non-invasive strategy benefits this population remains unclear.
Does conservative (non-invasive) treatment increase the risk of MACE in elderly patients with NSTEMI compared to invasive treatment?
Cohort (n=2,239)
Yes
Does conservative (non-invasive) treatment increase the risk of MACE in elderly patients with NSTEMI compared to invasive treatment?
Answers are grounded in this paper and cite their sources.
Conservative management in elderly NSTEMI patients is associated with a threefold higher MACE.
Background Optimal treatment for elderly patients with non-ST-segment elevation myocardial infarction (NSTEMI) is still debated. Whether a non-invasive strategy benefits this group of patients remains unclear. Methods Acute coronary syndrome (ACS) patients admitted to four Swiss University Hospitals and enrolled in the multicenter SPUM registry between 2009 and 2017 were followed prospectively for 1 year. The composite primary endpoint was major adverse cardiovascular (MACE); i.e., non-fatal stroke, non-fatal myocardial infarction (MI) or death) at 1 year. Elderly patients were defined as age ≥ 75 years. Multivariable-adjusted Cox proportional hazard regression models were fit to estimate MACE risk in the overall population and in the elderly. Results Out of 4’787 ACS patients, 2239 (46.8%) presented with NSTEMI. Among these 203 (9.0%) patients did not undergo coronary angiography and were treated conservatively. These patients were older (69 vs 65 years, p=0.002), had more often traditional cardiovascular (CV) risk factors such as hypertension (70.0% vs 63.0%, p=0.004) and diabetes (p=0.001) and were more likely to have a complex history of CV disease, such as previous MI (30.0 vs 16.0%), previous percutaneous (30.0 vs 19.0%) or surgical revascularization (14.0% vs 6.0%) as well as a history of heart failure (5.0% vs 2.0%, all p<0.001). NT-pro BNP (880 vs 498 pm/ml, p<0.001) was significantly increased in these patients, who presented more frequently impaired renal function (eGFR 83.8 vs 88.5 ml/min, p=0.002). Hospital length of stay was also significantly higher in these patients (7 vs 2 days, p<0.001). At 1 year, patients treated conservatively had a higher rate of MACE (19.2% vs 10.1%, p<0.0001). Elderly patients presented an even higher risk of MACE (33.9% vs 17.3%, p=0.0003), that persisted after adjustment for baseline characteristics (Adj. HR 3.12, 95%CI 1.49-6.66, p=0.003). Conclusions Our real-world data suggest that a non-invasive treatment of elderly patients with NSTEMI is associated with an increased risk of MACE at 1 year follow-up. These observations may in part be related to their less favorable clinical phenotype and an less optimal management of their condition, underlining the need for a personalized risk stratification using AI-supported risk scores of old patients in order to improve cardiovascular outcome.Baseline characteristics. Cumulative risk of MACE in NSTEMI.
No takes yet. Share an insight, caveat, or question.
Denegri et al. (2025) conducted a cohort in Non-ST-segment elevation myocardial infarction (NSTEMI) (n=2,239). Non-invasive treatment vs. Invasive treatment (coronary angiography) was evaluated on Major adverse cardiovascular events (MACE; non-fatal stroke, non-fatal MI, or death) at 1 year (HR 3.12, 95% CI 1.49-6.66, p=0.003). Non-invasive treatment of elderly patients with NSTEMI was associated with an increased risk of major cardiovascular events at 1 year compared to invasive management.
Synapse has enriched 10 related papers. Consider them for comparative context: